A recent study has published on Nature Communication (open-access to public, authors will pay roughly $5000 to the publisher) which proposed a new strategy to deliver desired antibodies using mRNA to ultimately cure diseases. A series of questions raised by reviewers can be found here. Supporting information does not contain much useful information.
How does this strategy differ from the traditional method?
The traditional method is often injecting antibodies to patients. This means that the pharmaceutical companies have to product customized antibodies for particular diseases. This could be expensive due to the overhead cost (development and manufacturing costs).
Instead the recent study introduced an encoded mRNA sequence to the host. Suppose the mRNA sequence can be uptaken by the cells. Then the cells can start producing desired antibodies to help curing the diseases.
- Vector-mediated antibody gene transfer (injecting modified nucleic acids).
- Recombinant protein production (synthetic antibodies).
- Adeno-associated virus (AAV, a single strand DNA virus).
- Immunogenicity (cell-mediated immune responses, destroy external materials by the host).
- Modified nucleosides (1-methylpseudouridine) mRNA is non-immunogenic (modified mRNA with this method can prevent the host immune response).
- Lipid nanoparticles are carriers for mRNA (observed high protein production?)
- Nucleoside-modified mRNA encapsulated into lipid nanoparticles, a tool for protein therapy.
- The light and heavy chains of VRC01, neutralizing antibody against HIV-1.